TY - JOUR
T1 - A comparative proteomics analysis of peritoneal dialysate before and after the occurrence of peritonitis episode by mass spectrometry
AU - Tyan, Yu Chang
AU - Su, Shih Bin
AU - Ting, Sing Sing
AU - Wang, Hsien Yi
AU - Liao, Pao Chi
N1 - Funding Information:
The authors thank the Center of Excellence for Environmental Medicine, Kaohsiung Medical University for the assistance in protein identification and the National Cheng-Kung University Proteomics Research Core Laboratory for assistance in 2DE and mass spectrometry analyses. This work was supported by research grants NSC99-2923-M-006-001-MY3 , NSC100-2113-M-006-002-MY3 and NSC101-2325-B-006-003 from the National Science Council , and CMNCKU10013 from Chi-Mei Medical Center-National Cheng Kung University Research Foundation, Taiwan, Republic of China .
PY - 2013
Y1 - 2013
N2 - Background: Peritoneal dialysis (PD) is one of the therapeutic options for the end-stage renal disease (ESRD) patients. The peritoneal membrane is immersed in a high glucose concentration of the peritoneal dialysate, which may cause structural and functional damage. Peritonitis is one of the major complications of PD, which will accelerate the damage of peritoneal membrane by increasing the peritoneal permeability and decrease the ultrafiltration efficiency. It will cause the peritoneal membrane dysfunction and the patient may have fluid overload related complications or hemodialysis. Methods: To enhance our understanding of peritoneal dialysate, the peritoneal dialysate proteins were identified by 2-dimensional gel electrophoresis (2DE) combined with reverse phase nano-high performance liquid chromatography electrospray ionization tandem mass spectrometry (RP-nano-HPLC-ESI-MS/MS) followed by peptide fragmentation pattern. Results: We performed 2DE on the 12 peritoneal dialysate before/after peritonitis, and more than 350 spots were detected. Among these protein spots, 136 spots of the 2DE were excised, in-gel digested and identified by nano-HPLC-ESI-MS/MS. A total of 41 proteins were identified with high levels of confidence. Ten of these were significantly differentially expressed between the peritoneal dialysate samples before/after peritonitis. Conclusion: The present study was designed to establish optimal techniques to develop a proteomic map of peritoneal dialysate proteins. These proteins may not be new biomarkers; however, they may indicate a situation for possible drug treatment and can be the predictors of peritonitis for the validation study in the further.
AB - Background: Peritoneal dialysis (PD) is one of the therapeutic options for the end-stage renal disease (ESRD) patients. The peritoneal membrane is immersed in a high glucose concentration of the peritoneal dialysate, which may cause structural and functional damage. Peritonitis is one of the major complications of PD, which will accelerate the damage of peritoneal membrane by increasing the peritoneal permeability and decrease the ultrafiltration efficiency. It will cause the peritoneal membrane dysfunction and the patient may have fluid overload related complications or hemodialysis. Methods: To enhance our understanding of peritoneal dialysate, the peritoneal dialysate proteins were identified by 2-dimensional gel electrophoresis (2DE) combined with reverse phase nano-high performance liquid chromatography electrospray ionization tandem mass spectrometry (RP-nano-HPLC-ESI-MS/MS) followed by peptide fragmentation pattern. Results: We performed 2DE on the 12 peritoneal dialysate before/after peritonitis, and more than 350 spots were detected. Among these protein spots, 136 spots of the 2DE were excised, in-gel digested and identified by nano-HPLC-ESI-MS/MS. A total of 41 proteins were identified with high levels of confidence. Ten of these were significantly differentially expressed between the peritoneal dialysate samples before/after peritonitis. Conclusion: The present study was designed to establish optimal techniques to develop a proteomic map of peritoneal dialysate proteins. These proteins may not be new biomarkers; however, they may indicate a situation for possible drug treatment and can be the predictors of peritonitis for the validation study in the further.
UR - http://www.scopus.com/inward/record.url?scp=84877624268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877624268&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2012.10.010
DO - 10.1016/j.cca.2012.10.010
M3 - Article
C2 - 23078846
AN - SCOPUS:84877624268
SN - 0009-8981
VL - 420
SP - 34
EP - 44
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -